Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2953–2976 of 10,825 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Developmental Defect Clear all

Conditions: Sickle Cell Disease
Interventions: Voxelotor; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 6 Months and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 3 more

Conditions: FAP, Familial Amyloid Polyneuropathy, TTR, Transthyretin, Amyloidosis
Interventions: Inotersen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 82 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 9
States / cities: Orange, California • Indianapolis, Indiana • Baltimore, Maryland + 5 more

Conditions: Hemophilia A
Interventions: Efanesoctocog Alfa BIVV001; Drug
Lead sponsor: Sanofi; Industry
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 28
States / cities: Gilbert, Arizona • Loma Linda, California • Los Angeles, California + 23 more

Conditions: Fibrodysplasia Ossificans Progressiva
Interventions: Andecaliximab, Placebo; Drug
Lead sponsor: Ashibio Inc; Industry
Eligibility: 2 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania

Conditions: Canavan Disease
Interventions: rAAV-Olig001-ASPA, Levetiracetam, Prednisone; Drug
Lead sponsor: Myrtelle Inc.; Industry
Eligibility: 3 Months to 60 Months
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: Atrial Fibrillation, Stroke, Valve Disease, Heart, Atrial Septal Defect, Patent Foramen Ovale, Mitral Valve Disease, Tricuspid Valve Disease, Aortic Valve Disease
Interventions: ICE Image guidance; Device
Lead sponsor: Philips Clinical & Medical Affairs Global; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Fetal Growth Restriction (FGR), Placental Insufficiency, Preeclampsia, Still Births, Pregnancy, Pregnancy Complications, Pregnancy Outcomes, Ultrasound
Interventions: ultrafast power Doppler imaging (uPDI) / quantitative ultrasound (QUS); Device
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Neurofibromatosis
Interventions: Gleevec; Drug
Lead sponsor: Indiana University; Other
Eligibility: 3 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Gonadal Dysgenesis, Turner's Syndrome
Interventions: Growth Hormone (Humatrope); Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: Female only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1987 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hemophilia B
Interventions: rFIXFc; Drug
Lead sponsor: Bioverativ Therapeutics Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 6
States / cities: Chicago, Illinois • Indianapolis, Indiana • Boston, Massachusetts + 3 more

Conditions: Retinitis Pigmentosa
Interventions: Not listed
Lead sponsor: Second Sight Medical Products; Industry
Eligibility: 25 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 17
States / cities: Los Angeles, California • Denver, Colorado • Miami, Florida + 13 more

Conditions: Hemophilia A
Interventions: rAHF-PFM; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: Male only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 37
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 30 more

Conditions: Type 1 Diabetes, Diabetes Insipidus, Diabetes Mellitus, Wolfram Syndrome
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 1 Day and older
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Dilated Cardiomyopathy, Lamin A/C Gene Mutation
Interventions: ARRY-371797 (PF-07265803), Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 56
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 26 more

Conditions: Rett Syndrome
Interventions: triheptanoin; Drug
Lead sponsor: Center for Rare Neurological Diseases, Norcross, GA; Other
Eligibility: 2 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Norcross, Georgia

Conditions: Heart Defects, Congenital, Heart Septal Defects, Ventricular, Heart Failure, Congestive
Interventions: Enalapril, Placebo; Drug · Other
Lead sponsor: University of Utah; Other
Eligibility: Up to 18 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 6
States / cities: Boston, Massachusetts • New York, New York • Durham, North Carolina + 3 more

Conditions: Cystic Fibrosis, Hypoestrogenism
Interventions: Transdermal estrogen, Progesterone; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 0 Years to 100 Years · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Thyroid Eye Disease
Interventions: VRDN-003, Placebo; Drug
Lead sponsor: Viridian Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 34
States / cities: Scottsdale, Arizona • Canoga Park, California • Huntington Beach, California + 25 more

Conditions: Pantothenate Kinase-Associated Neurodegeneration
Interventions: CoA-Z, Placebo; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 3 Months to 89 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Non Malignant Disorders, Immunodeficiencies, Congenital Marrow Failures, Hemoglobinopathies, Inborn Errors of Metabolism, Sickle Cell, Thalassemia, Lysosomal Storage Disease
Interventions: Unrelated Umbilical Cord Blood Transplant, Reduced Intensity Conditioning; Biological · Drug
Lead sponsor: Duke University; Other
Eligibility: Up to 21 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Epilepsy, GLUT1DS1, Glut1 Deficiency Syndrome 1, Autosomal Recessive, Glucose Metabolism Disorders, Glucose Transport Defect, Glucose Transporter Type 1 Deficiency Syndrome, Glucose Transporter Protein Type 1 Deficiency Syndrome
Interventions: Triheptanoin; Drug
Lead sponsor: Juan Pascual; Other
Eligibility: 2 Years to 35 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hyperuricemia, Gout
Interventions: Allopurinol; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Phenylketonurias
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: Not listed
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 3
States / cities: Atlanta, Georgia • Decatur, Georgia

Conditions: Cancer, Cardiovascular Diseases, Prenatal Condition, Reproductive Condition, Genetic Condition
Interventions: Genetic counseling months 4-15, Genetic counseling months 6-15, Genetic counseling months 8-15, Genetic counseling at months 10-15, Genetic counseling at months 12-15, Genetic counseling at months 14-15; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 1,094 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

Open-Label Extension of Voxelotor

Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy

A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A

A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease

Philips Intracardiac Echocardiography (ICE) Clinical Registry

Placental Imaging Techniques

Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

Effect of Biosynthetic Growth Hormone and/or Ethinyl Estradiol on Adult Height in Patients With Turner Syndrome

Phase I/IIa Study of FIXFc in Hemophilia B Patients

New Enrollment Post-Approval Study of the Argus® II Retinal Prosthesis System

ADVATE Post Authorization Safety Surveillance

Tracking Neurodegeneration in Early Wolfram Syndrome

A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation

Treatment of Mitochondrial Dysfunction in Rett Syndrome With Triheptanoin

Angiotensin Converting Enzyme Inhibition in Children With Mitral Regurgitation

Estrogen Supplementation and Bone Health in Women With CF

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)

CoA-Z in Pantothenate Kinase-associated Neurodegeneration (PKAN)

Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders

Treatment Development of Triheptanoin (G1D)

Genetics of Hyperuricemia Therapy in Hmong

Testing of Four Home Phenylalanine Monitoring Prototype Devices

GC-PRO Intervention